Cargando…

A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation

Antibody-induced complement activation may cause injury of the neuromuscular junction (NMJ) and is thus considered as a primary pathogenic factor in human myasthenia gravis (MG) and animal models of experimental autoimmune myasthenia gravis (EAMG). In this study, we tested whether CRIg/FH, a targete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Jie, Zhao, Rui, Yan, Chong, Luo, Sushan, Xi, Jianying, Ding, Peipei, Li, Ling, Hu, Weiguo, Zhao, Chongbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825366/ https://www.ncbi.nlm.nih.gov/pubmed/35154091 http://dx.doi.org/10.3389/fimmu.2022.746068

Ejemplares similares

The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice
por: Shi, Yu, et al.
Publicado: (2019)

Pneumonia in myasthenia gravis: Microbial etiology and clinical management
por: Su, Manqiqige, et al.
Publicado: (2022)

Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort
por: Shi, Jianquan, et al.
Publicado: (2021)

Increased Frequency of Myeloid-Derived Suppressor Cells in Myasthenia Gravis After Immunotherapy
por: Wang, Yan, et al.
Publicado: (2022)

Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study
por: Zhong, Huahua, et al.
Publicado: (2022)

Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis
Publicado: (1978)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Inflammation and autoimmune myasthenia gravis
por: Huda, Ruksana
Publicado: (2023)

Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats
por: Rinaldi, Elena, et al.
Publicado: (2019)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis
por: Huan, Xiao, et al.
Publicado: (2022)

Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China
por: Zhou, Yufan, et al.
Publicado: (2022)

Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis
por: Feng, Xuelin, et al.
Publicado: (2021)

Short-term outcome prediction for myasthenia gravis: an explainable machine learning model
por: Zhong, Huahua, et al.
Publicado: (2023)

Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases
por: Zhu, Ying, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis
por: Su, Manqiqige, et al.
Publicado: (2022)

Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
por: Fichtner, Miriam L., et al.
Publicado: (2020)

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies
Publicado: (1976)

Autoimmune Thyroiditis and Myasthenia Gravis
por: Lopomo, Angela, et al.
Publicado: (2017)

Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs
Publicado: (1975)

Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
por: Wang, Zhen, et al.
Publicado: (2017)

Muscle-Specific Kinase Myasthenia Gravis
por: Borges, Lucia S., et al.
Publicado: (2020)

To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis
por: Zhou, Qian, et al.
Publicado: (2021)

Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis
por: Soltys, Jindrich, et al.
Publicado: (2012)

Prophylactic Effect of Probiotics on the Development of Experimental Autoimmune Myasthenia Gravis
por: Chae, Chang-Suk, et al.
Publicado: (2012)

A Randomized Control Study on the Efficacy of Thymectomy in Patients with Nonthymomatous (without Chest Tumor) Myasthenia Gravis
por: Chen, Ji, et al.
Publicado: (2020)

Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome
por: Gómez Delgado, Irene, et al.
Publicado: (2021)

Experimental autoimmune myasthenia gravis and CD5+ B-lymphocyte expression.
por: Lee, K. W., et al.
Publicado: (1999)

A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1–T146
por: Consonni, Alessandra, et al.
Publicado: (2017)

Complement deposition at the neuromuscular junction in seronegative myasthenia gravis
por: Hoffmann, Sarah, et al.
Publicado: (2020)

Role of miRNAs in Normal and Myasthenia Gravis Thymus
por: Cron, Mélanie A., et al.
Publicado: (2020)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Autoimmune Myasthenia Gravis after Sternal Fracture
por: Petersen, Jens A., et al.
Publicado: (2012)

Gender differences in quality of life among patients with myasthenia gravis in China
por: Dong, Dong, et al.
Publicado: (2020)

Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo
por: Hepburn, Natalie J., et al.
Publicado: (2008)

Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis
por: Wang, Shumin, et al.
Publicado: (2021)

Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging
por: Fu, Wenxian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dliuemkojm5c47158dg9m73l85